17.4 C
New York
Monday, June 8, 2026

Tag: obligation

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

AMB-702 demonstrates superior target coverage and efficacy in lean non-human primates The dataset was shared as part of a poster presentation at the American Diabetes...

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Orca Energy Group Inc. Announces Completion of Q1 2026 Interim Filings

TORTOLA, British Virgin Islands, June 05, 2026 (GLOBE NEWSWIRE) -- Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announces that it has filed its condensed consolidated interim (unaudited) financial statements and management’s discussion and analysis for the three month period ended March 31, 2026 (“Q1 2026”) with the Canadian securities regulatory authorities. All amounts are in United States dollars (“$”) unless otherwise stated.

AURION OBTAINS SECURITYHOLDER APPROVAL FOR PLAN OF ARRANGEMENT WITH AGNICO EAGLE MINES LIMITED

ST. JOHN'S, NL, June 5, 2026 /CNW/ - Aurion Resources Ltd. (TSXV: AU) (OTCQX: AIRRF) ("Aurion") is pleased to announce that, at its special meeting (the...

Vireo Growth Inc. Completes Acquisition of Bridgewell Agribusiness LLC and Plans to Acquire Dispensaries in Nevada and Maryland

Vireo Growth Inc. completes acquisition of Bridgewell Agribusiness LLC and plans to acquire dispensaries in Nevada and Maryland.

BIRKS GROUP ANNOUNCES THE CLOSING OF A NEW TERM LOAN FACILITY WITH GORDON BROTHERS REPLACING ITS FORMER TERM LOAN FACILITY AND THE EXTENSION OF...

All figures presented herein are in Canadian dollars, unless indicated otherwise.MONTREAL, June 5, 2026 /CNW/ - Birks Group Inc. ("Birks Group" or the "Company")...

Boralex Obtains Final Court Approval of the Arrangement with Brookfield and La Caisse

MONTRÉAL, June 05, 2026 (GLOBE NEWSWIRE) -- Boralex Inc. ("Boralex" or the "Corporation") (TSX: BLX) announced today that the Corporation has obtained a final order from the Superior Court of Québec (Commercial Division) approving the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") involving the Corporation and BIF Thunder Holdings Inc., a newly-formed entity to be jointly owned by Brookfield Infrastructure Fund V and/or its affiliates (collectively, "Brookfield") and Caisse de dépôt et placement du Québec. This final court approval follows the shareholder approval that was obtained at the annual and special meeting of the Corporation's shareholders held on Thursday, June 4, 2026.

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2026 (the “Grant Date”), ORIC granted a total of 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began their employment with ORIC in May 2026.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of GRAIL, Inc. Common Stock...

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

Uniti Group Inc. Announces Pricing of $1.1 Billion Kinetic Fiber Securitization Notes Offering

LITTLE ROCK, Ark., June 05, 2026 (GLOBE NEWSWIRE) -- Uniti Group Inc. (the “Company,” “Uniti,” or “we”) (Nasdaq: UNIT) today announced that Kinetic ABS Issuer LLC, a limited-purpose, bankruptcy remote subsidiary of Uniti (the “Issuer”), has priced its offering of $1,140,710,000 aggregate principal amount of secured fiber network revenue term notes, consisting of $805,210,000 5.834% Series 2026-2, Class A-2 term notes, $134,200,000 6.224% Series 2026-2, Class B term notes and $201,300,000 7.536% Series 2026-2, Class C term notes, each with an anticipated repayment date in June 2033 (collectively, the “Notes”). Collectively, the Notes have a weighted average coupon rate of approximately 6.180%. The Notes are expected to be secured by certain residential fiber network assets and related customer agreements in the States of Texas, Arkansas, Kentucky, Ohio, Georgia, Iowa, Alabama, Florida, North Carolina and Oklahoma. Each of the Issuer and its direct parent entity and subsidiaries are designated as “unrestricted subsidiaries” under Uniti’s credit agreement and the indentures governing its outstanding senior notes. The offering is expected to close on July 15, 2026.

Hallador Selected by Department of Energy for ~$27.2 Million Award Negotiations

TERRE HAUTE, Ind., June 05, 2026 (GLOBE NEWSWIRE) -- Hallador Energy Company (Nasdaq: HNRG) (“Hallador” or the “Company”) today announced that its subsidiary, Hallador Power Company, LLC (“Hallador Power”), was selected by the U.S. Department of Energy’s (“DOE”) Hydrocarbons and Geothermal Energy Office to begin award negotiations for up to $27.2 million, in potential federal funding to modernize the Merom Generating Station (“MGS”) located in Merom, Indiana. Total project cost is estimated to be approximately $56.9 million. The comprehensive modernization project is designed to upgrade MGS’s water management systems to position the plant for future federal Effluent Limitation Guidelines (ELG) requirements. This project will help modernize the delivery of reliable and flexible energy to MISO zone 6.

Did NIKE, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsObligation